Push Pull Trends in Joint Replacement Market Keep Growth Steady
Over the next twelve months, BioMedGPS projects the US Joint Replacement Market will grow in the low single digits at approximately 3%. This slow but steady growth is consistent with past years as the push pull of market trends keeps it in check. Gaining share in this era will require companies to navigate the changing political and economic landscape and to deliver solutions beyond launching the latest widget...
SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.
One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.
At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...
India spoke loud and clear with extreme pricing caps on total knee replacements, while CMS sends mixed messages on controlling costs in the US
Outside the US the Total Joints Market softened during Q217, offsetting stable to strengthening results in US Knees and Hips, with the WW Market (as reported) growing +0.7%. Countries such as India are working to reduce the cost burden of joint replacement surgery, while in the US, the Centers for Medicaid & Medicare Services (CMS) is sending mixed messages keeping reimbursement rates relatively flat while proposing reductions to its Comprehensive Care for Joint Replacement bundled payments initiative...
Reducing the recurrence of diabetic foot ulcers (DFU) or increasing ulcer free days is critical for patients with diabetes, as recurrence rates are 40% at one year, 66% at three years, and 75% at five years. At the DF Con meeting in Houston in March, BioMedGPS interviewed David G. Armstrong, DMP, MD, PhD, regarding his research on the use of fat grafting as a means to reduce recurrence of DFUs. Today, fat grafting is being rapidly adopted in plastic and reconstructive surgery, but is now being explored for care of the diabetic foot.
Irvine, CA (PRWEB) September 12, 2017
BioMedGPS, the leading provider of real-time analytics and strategic intelligence of the orthopedic/spine, wound care, regenerative medicine and neuro therapies markets, announces expanded coverage of SmartTRAK Business Intelligence for the European market with the addition of modules in SmartTRAK EU Extremities and EU Trauma.
SmartTRAK will be at this year's #AVA2017 Association for Vascular Access 2017 Annual Scientific Meeting in Phoenix, Arizona. This year's conference promises to be invaluable for industry learnings and networking. Susan Paquette, VP & General Manager SmartTRAK Wound, will also be in attendance, covering the latest research and technologies and participating in this year's informative agenda.
Durham-based Bioventus has received approval from the U.S. Food and Drug Administration for its treatment, Durolane.
The single-injection product treats knee osteoarthritis pain. The company plans to launch Durolane in the U.S. early next year.
Citing BioMedGPS SmartTRAK, Bioventus CEO Tony Bihl said in an email that “the 2016 entire HA market in the US (1-shot, 2-shot, 3-shot and 5-shot) was about $979 million.”
International Neuromodulation Society (INS) President Tim Deer, MD discusses important research results as well as key trends and technologies in neuromodulation.
Timothy Deer, MD, FIPP, President of the International Neuromodulation Society (INS), at the INS 13th Annual Congress May 26-June 3 highlighted key studies, trends and technologies in neuromodulation in an interview with SmartTRAK in Edinburgh, Scotland...
Max Retail Pricing for Knees in India Dropping up to 78%
The Indian Government enacted price controls for knee implants capping the price significantly below current market rates. According to a report in IndiaToday , the move is the latest step in the government’s move to bring down the cost of medical devices and pharmaceuticals. The price controls for knee replacement implants caps the price of CoCr knees at ~$852 (54,720 rupees). Ananth Kumar, Minister of Chemicals and Fertilisers, stated current implants are priced at up to ~$3,895 (250K rupees) at Indian hospitals...
SmartTRAK is the Medtech industry’s only global Insights-as-a-Service solution for the Orthopedics, Wound Care, Regenerative Medicine and Neuro Therapy markets. SmartTRAK’s propriety methodology turns disparate data from hundreds of sources into powerful insights customers can rely on as the trusted source for strategic decision-making. The SmartTRAK enterprise platform includes rich daily updates, comprehensive market coverage and simple-to-use tools and dashboards for market, product and financial analysis. Customers leveraging the SmartTRAK platform also have direct access to market experts for inquiries and advisory services.
Robust growth is predicted for the US OrthoBio market, driving revenues to over $4B by 2021E according to SmartTRAK projections.